Better Rejection-Free Survival at Three Years in Kidney Transplant Recipients With Model-Informed Precision Dosing of Mycophenolate Mofetil.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
19 Feb 2024
19 Feb 2024
Historique:
received:
30
11
2022
accepted:
25
01
2024
medline:
19
2
2024
pubmed:
19
2
2024
entrez:
19
2
2024
Statut:
aheadofprint
Résumé
The clinical impact of individual dose adjustment of mycophenolate mofetil is still debated, due to conflicting results from randomized clinical trials. This retrospective study aimed to compare 3-year rejection-free survival and adverse effects between adult kidney transplant recipients (KTRs) with or without mycophenolate mofetil model-informed precision dosing (MIPD). MIPD is defined here as mycophenolic acid area under the curve (AUC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Bergan, S. et al. Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther. Drug Monit. 43, 150-200 (2021).
van Gelder, T. et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68, 261-266 (1999).
Metz, D.K. et al. Optimizing mycophenolic acid exposure in kidney transplant recipients: time for target concentration intervention. Transplantation 103, 2012-2030 (2019).
Meziyerh, S. et al. Tacrolimus and mycophenolic acid exposure are associated with biopsy-proven acute rejection: a study to provide evidence for longer-term target ranges. Clin. Pharmacol. Ther. 114, 192-200 (2023).
de Winter, B.C.M., Mathot, R.A., Sombogaard, F., Vulto, A.G. & van Gelder, T. Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. Clin. J. Am. Soc. Nephrol. 6, 656-663 (2011).
Knight, S.R. & Morris, P.J. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 85, 1675-1685 (2008).
Kuypers, D.R.J. et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin. J. Am. Soc. Nephrol. 5, 341-358 (2010).
Sommerer, C. et al. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br. J. Clin. Pharmacol. 69, 346-357 (2010).
Tett, S.E. et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant. Rev. (Orlando) 25, 47-57 (2011).
van Gelder, T. et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 86, 1043-1051 (2008).
Gaston, R.S. et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am. J. Transplant. 9, 1607-1619 (2009).
Le Meur, Y. et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am. J. Transplant. 7, 2496-2503 (2007).
Le Meur, Y. et al. Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil. Transplantation 92, 1244-1251 (2011).
Le Guellec, C. et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin. Pharmacokinet. 43, 253-266 (2004).
Prémaud, A. et al. Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther. Drug Monit. 27, 354-361 (2005).
Musuamba, F.T. et al. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Clin. Pharmacokinet. 48, 745-758 (2009).
de Winter, B.C.M. et al. Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients. Clin. Pharmacokinet. 51, 29-39 (2012).
Saint-Marcoux, F., Vandierdonck, S., Prémaud, A., Debord, J., Rousseau, A. & Marquet, P. Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients. Ther. Drug Monit. 33, 285-294 (2011).
Labriffe, M. et al. Mycophenolate mofetil dose adjustment in pediatric kidney transplant recipients. Ther. Drug Monit. 45, 591-598 (2023).
Villeneuve, C. et al. Evolution and determinants of health-related quality-of-life in kidney transplant patients over the first 3 years after transplantation. Transplantation 100, 640-647 (2016).
Villeneuve, C. et al. Adherence profiles in kidney transplant patients: causes and consequences. Patient Educ. Couns. 103, 189-198 (2020).
Billat, P.A. et al. Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. Pharmacol. Res. 111, 501-508 (2016).
Stamenic, D. et al. A prognostic tool for individualized prediction of graft failure risk within ten years after kidney transplantation. J. Transp. Secur. 2019, 7245142 (2019).
Rosenbaum, P.R. & Rubin, D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 70, 41-55 (1983).
van Gelder, T. et al. Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation 89, 595-599 (2010).
Brooks, J.M. & Ohsfeldt, R.L. Squeezing the balloon: propensity scores and unmeasured covariate balance. Health Serv. Res. 48, 1487-1507 (2013).
Okoli, G.N., Sanders, R.D. & Myles, P. Demystifying propensity scores. Br. J. Anaesth. 112, 13-15 (2014).
Cho, H., Yu, H., Shin, E., Kim, Y.H., Park, S.K. & Jo, M.W. Risk factors for graft failure and death following geriatric renal transplantation. PLoS One 11, e0153410 (2016).
Ojo, A.O., Wolfe, R.A., Held, P.J., Port, F.K. & Schmouder, R.L. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 63, 968-974 (1997).
Betjes, M.G.H., Sablik, K.S., Otten, H.G., Roelen, D.L., Claas, F.H. & de Weerd, A. Pretransplant donor-specific anti-HLA antibodies and the risk for rejection-related graft failure of kidney allografts. J. Transplant. 2020, 5694670 (2020).
US Food and Drug Administration. Guidance for industry and Food and Drug Administration staff: use of real-world evidence to support regulatory decision-making for medical devices <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices> (2017) Accessed December 9, 2023.